Senores Pharmaceuticals IPO
Company Background
Incorporated in December 2017, Senores Pharmaceuticals has rapidly established itself in the pharmaceutical industry, catering primarily to regulated markets and expanding its footprint in emerging economies. The company has launched 55 products spanning key therapeutic areas, including antibiotics and anti-fungal treatments, as of September 30, 2024.
Senores operates three R&D facilities in India and the US and has partnerships with distributors and hospitals across various Indian states. Its manufacturing expertise includes critical care injectables and APIs, further solidifying its position in the market.
Product Portfolio
Senores Pharmaceuticals’ portfolio features a diverse range of products tailored for regulated markets. Key offerings include:
Amphetamine Sulfate Tablets
Hydroxychloroquine Sulfate Tablets
Morphine Sulfate Tablets
Cyclobenzaprine Hydrochloride Tablets
IPO Objectives
The proceeds from the IPO will be utilized to:
Invest in Havix for facility setup.
Repay existing borrowings, including those of Havix.
Meet capital requirements for SPI and Ratnatris working capital.
Strengths and Growth Strategy
Senores Pharmaceuticals’ strengths lie in its ability to expand sterile injection manufacturing, reduce operational debt, and allocate funds strategically to subsidiaries. The company is also focused on growth through acquisitions, further enhancing its market presence.
Risks to Consider
While the company demonstrates significant potential, investors should consider risks such as high dependence on borrowed funds, regulatory hurdles in manufacturing, and potential market volatility that could impact growth plans. Senores Pharmaceuticals IPO: Key Details
IPO Dates: 20-23 December 2024
Price Band:₹372 to ₹391 per share
Lot Size: 38 Shares
Issue Size: ₹582.11 Cr
Retail Quota: 10%
GMP: 30% (only for information)
DISCLAIMER: No financial information whatsoever published anywhere here should be construed as an offer to buy or sell securities, or as advice to do so in any way whatsoever. All matters published here are purely for educational and information purposes only and under no circumstances should be used for making investment decisions. Readers must consult a qualified financial advisor before making any actual investment decisions, based on the information published here. Any reader making decisions based on any information published here does so entirely at their own risk. Investors should bear in mind that any investment in the stock market is subject to unpredictable market-related risks. The author has no plans to invest in this offer and also the author does not recommend investing in any offer published on this website.